Amneal Pharmaceuticals delivered a substantial rebound in profitability in 2025, driven by growth across its Affordable Medicines, Specialty, and AvKARE segments. Operating income surged 58% year-over-year to $394 million, supported by a diversified portfolio emphasizing complex generics and biosimilars with barriers to entry. Legal challenges including antitrust litigation, opioid-related settlements, and government investigations continue to pose uncertainty. While robust cash flows and capital expenditure investments underpin operational capacity expansion, negative equity reflects historical leverage pressures.